Effects of estrogen supplementation for patients with thin endometrial lining receiving oral clomiphene citrate

Estrogen supplementation for thin endometrium in patients undergoing ovulation induction with clomiphene citrate: a randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10360127

Enrollment

124

Registered

2021-01-28

Start date

2021-01-31

Completion date

Unknown

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary or secondary subfertility Urological and Genital Diseases

Interventions

Patients diagnosed with either primary or secondary subfertility undergoing ovulation induction with clomiphene citrate in preparation for IUI (intrauterine insemination) or TSI (timed sexual intercou

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women diagnosed with primary or secondary subfertility undergoing ovulation induction using clomiphene citrate in preparation for intrauterine insemination (IUI) or timed sexual intercourse (TSI)

Exclusion criteria

Exclusion criteria: 1. Planned IVF 2. Diagnosed with an endometrial polyp 3. Using GnRH Agonist 4. Systemic diseases (e.g. autoimmune, cardiac, liver, thyroid disease or malignancy)

Design outcomes

Primary

Measure	Time frame
Endometrial thickness measured using transvaginal sonogram at initial visit (baseline), between days 8-10 of the current cycle and 4 days later	—

Secondary

Measure	Time frame
1. Pregnancy rate measured using the urinary pregnancy test or serum B-HCG when the patient misses her period the subsequent month 2. Miscarriage rate measured using the transabdominal/transvaginal sonogram and clinical assessment if the patient experiences early pregnancy complications such as bleeding or passing out of products of conception 3. Nausea and vomiting assessed where the patient records having any of these symptoms during her visit 4 days after being randomised	—

Measure

Time frame

1. Pregnancy rate measured using the urinary pregnancy test or serum B-HCG when the patient misses her period the subsequent month 2. Miscarriage rate measured using the transabdominal/transvaginal sonogram and clinical assessment if the patient experiences early pregnancy complications such as bleeding or passing out of products of conception 3. Nausea and vomiting assessed where the patient records having any of these symptoms during her visit 4 days after being randomised

—

Countries

Malaysia

Contacts

Public ContactRajeev Kumar Rajaratnam

rajeev.kumar@ummc.edu.my+60 (0)133962212

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026